Project Grant R01AI184418
Award Date
8/6/24
Completion Date
7/31/29
Dollars Obligated
$1.4M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Davis, CA, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,332,155 to Emory University to conduct research focused on developing immunotherapies to cure HIV in SHIV-infected infant macaques. The key objectives are to evaluate strategies that leverage broadly neutralizing antibodies (bNAbs) in combination with virus reactivation, innate immune stimulation, and attachment...
This Project Grant award for $1,314,572.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research aimed at developing a cure strategy for HIV-1 using CD4-mimetic compounds (CD4MCs) and CD4-induced antibodies (CD4I Abs). The research, conducted by Yale University, leverages the recent discovery of a new class of indoline CD4MCs that display improved antiviral potency and breadth...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $862,398 to the Fred Hutchinson Cancer Center in Seattle, WA over a 5-year period starting on August 1, 2025. The goal of this project is to develop novel chimeric antigen receptor (CAR) T-cell therapies that can selectively target and deplete the PD-1+ HIV/SIV reservoir in non-human primate models. The research aims to advance understanding of...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $800,389.00 to Emory University to evaluate the safety and therapeutic potential of a novel HIV treatment strategy. The goal is to develop a combination therapy using soluble IL-15/IL-15RA-FC and TGF-beta pathway blockade, along with therapeutic vaccination, to enhance and restore anti-viral immunity and lead to sustained viral...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $824,331 to the Trustees of Boston College to conduct research on "Understanding Formation and Dynamics of the SIV Reservoir." The project aims to investigate the early establishment and persistence of viral reservoirs in HIV/SIV infection, with a focus on the potential role of naive CD4+ T cells in...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel HIV cure strategy by targeting CD127-expressing tissue reservoir cells. The total funding amount is $250,791.00, with an award date of August 6, 2024 and an ultimate completion date of July 31, 2026. The key products and services to be delivered under this grant include: Utilizing an ex vivo...
This $812,810 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at Emory University to generate highly differentiated natural killer (NK) cells and evaluate their synergistic effects with broadly neutralizing antibodies in reducing the SIV reservoir and establishing viral control in the absence of antiretroviral therapy (ART). The key objectives are to: 1) define...
This Project Grant award, valued at $3,302,677.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award will support research at Oregon Health & Science University (OHSU) focused on using multimodal positron emission tomography (PET) imaging to directly visualize sites of simian immunodeficiency virus (SIV) persistence and identify early tissue foci of viral rebound in...
This $128,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of novel chimeric antigen receptor (CAR) T cell therapies to eliminate HIV reservoirs in non-human primate models. The goal is to engineer a second-generation anti-PD-1 CAR T cell therapy that can more specifically and safely deplete the pool of HIV-infected T follicular helper (Tfh) cells, which...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $884,322 to support research into the mechanisms that create and sustain the HIV reservoir - a population of latently infected cells that persists during suppressive antiretroviral therapy and prevents a cure for HIV. The research team, led by Dr. Reeves and collaborators at the Fred Hutchinson Cancer...